Industry Information

Update September 03, 2021

54 varieties have been reviewed! 15 varieties are the first to have reviewed, Nanjing Zhengda has the most sunny days, Yichang Renfu, Qilu...

According to the consistency evaluation analysis system of Yaozhi Data Enterprise Edition, 68 new acceptance numbers for consistency evaluation were added in August 2021; 77 approvals (including 9...

Update September 02, 2021

Interim Report: CRO's "differentiation" characteristics are highlighted in the first half of the year, and the growth rate of preclinical CRO is higher

On July 2, CDE issued the "Clinical Value-Oriented Anti-tumor Drug Clinical Research and Development Guidelines", which triggered a successive plunge in CRO concept stocks in the A-share and Hong...

Update August 28, 2021

Roche's $3 billion increase, what breakthroughs are needed for gene therapy?

On August 24, Shape Therapeutics (ShapeTX) announced a cooperation agreement with Roche, under which the two parties will jointly develop gene therapies for certain targets in Alzheimer's disease,...

Update August 26, 2021

Novartis CAR-T therapy second-line treatment of B-NHL clinical study failed! Gilead and BMS pursue the victory?

On August 24, Novartis announced that the CD19 CAR-T therapy Kymriah's second-line treatment of aggressive B-cell non-Hodgkin lymphoma (B-NHL) Phase III clinical BELINDA did not meet the primary...

Update August 25, 2021

Approved overseas for the first time! Ganli Pharmaceutical's insulin lispro obtained drug registration approval in Lebanon

Recently, Ganli Pharmaceutical Co., Ltd. (hereinafter referred to as "Ganli Pharmaceutical", stock code: 603087.SH) insulin lispro injection obtained drug registration approval in Lebanon. This is...

Update August 24, 2021

Hengrui Pharmaceuticals: In the first half of the year, the revenue was 13.3 billion, and the product pipeline was made public for the first time!

On August 19, Jiangsu Hengrui Pharmaceutical Co., Ltd. (Hengrui Pharmaceutical, 600276) released the first half of 2021 performance report. The financial report shows that in the first half of the...

Update August 23, 2021

Ranibizumab is approved for new indications, tens of billions of anti-VEGF biosimilars are gearing up

Recently, Novartis ranibizumab was approved for new indications, including retinopathy of prematurity (ROP) and diabetic retinopathy (DR). Previously approved indications include wet age-related...

Update August 20, 2021

Can the domestically produced replacement of insulin be realized?

In recent days, centralized procurement has been frequent. As soon as the special centralized procurement of Chinese patent medicines has come, the national procurement of insulin has begun! On...

Update August 19, 2021

Sinopharm China Bio-New Crown Inactivated Vaccine has no risk of thrombosis

Recently, Science Bulletin (Science Bulletin, Impact Factor: 11.780), an international authoritative natural science comprehensive academic journal, published Professor Qu Jieming, director of the...

Update August 18, 2021

Heavy! Special procurement of Chinese patent medicines struck, including more than 5 billion varieties

Recently, the National Medical Insurance Administration, in reply to the recommendation No. 4126 of the Fourth Session of the Thirteenth National People’s Congress, clearly stated that it will work...